Amgen, a biotechnology company, offers a strong pipeline of products and steady dividend distributions for its shareholders. Currently, Amgen pays $2.25 per share in dividends every quarter, totaling to an anticipated annual dividend yield of 2.8%. This is higher than the healthcare sector average of 1.5%, and there is potential for the dividend to increase in the future.
In terms of financial performance, Amgen reported 22% growth in product sales and revenue in the first quarter of 2024. Despite a slight decline in EPS due to operating expenses, the company remains in a strong financial position. Amgen has a diverse clinical pipeline with products in oncology, inflammation, rare diseases, and general medicine. They also have a program in place to treat obesity, showing their commitment to addressing various health issues.
Overall, investors can rely on Amgen for consistent dividend payments and growth opportunities in the biotechnology sector. With a track record of rewarding shareholders and a solid pipeline of products, Amgen is a reliable choice for those looking to invest in the healthcare industry.